The clinical outcomes of osteosarcoma are relatively dismal. As immunotherapy has revolutionized treatment for solid tumors, exploring novel immunotherapy‐related therapeutic targets for osteosarcoma is important. In this study, we aimed to establish the connection between RNA modification and immunotherapy in osteosarcoma to identify novel therapeutic targets. An RNA modification‐related signature was first developed using weight gene correlation network analysis and a machine‐learning algorithm, random forest. The signature's prognostic value, drug prediction, and immune characteristics were analyzed. EIF4G2 from the signature was next identified as a critical immunotherapy determinant. EIF4G2 could also promote tumor proliferation, migration, and M2 macrophage migration by single‐cell sequencing analysis and in vitro validation. Our signature and EIF4G2 are expected to provide valuable insights into the clinical management of osteosarcoma.

中文翻译：

---

RNA 修饰相关的 EIF4G2 是骨肉瘤免疫治疗的决定因素：单细胞测序分析

骨肉瘤的临床结果相对较差。由于免疫疗法彻底改变了实体瘤的治疗，因此探索骨肉瘤的新型免疫疗法相关治疗靶点非常重要。在这项研究中，我们旨在建立 RNA 修饰与骨肉瘤免疫治疗之间的联系，以确定新的治疗靶点。首先使用权重基因相关网络分析和机器学习算法随机森林开发了与 RNA 修饰相关的特征。分析了该特征的预后价值、药物预测和免疫特征。接下来，签名中的 EIF4G2 被确定为关键的免疫治疗决定因素。通过单细胞测序分析和体外验证，EIF4G2还可以促进肿瘤增殖、迁移和M2巨噬细胞迁移。我们的签名和 EIF4G2 有望为骨肉瘤的临床管理提供有价值的见解。